ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Higher BST2 Expression Promotes the Anti-HBV Effect of IFN-α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg-Positive Chronic Hepatitis B Patients

Chen, Jiaxuan; Hou, Jia; Na, Rong; Zhou, Bin; Hou, Jinlin*; Jiang, De-Ke*南方医科大学
Clinical Pharmacology and Therapeutics2024-2DOI: 10.1002/cpt.3120
13阅读
引用收藏
分享

摘要

We previously reported that an interferon (IFN)-inducible protein, BST2, was regulated by the JAK-STAT pathway activated by CD40, and subsequently suppressing hepatitis B virus (HBV) repliaction and transcription. The current research attempted to assess the impact of BST2 on the IFN-treated anti-HBV effect, and explore BST2 variants for predicting pegylated IFN alpha (PegIFN alpha) therapy response of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). Using an HBV-transfected cell model, the function of BST2 on HBV DNA replication and transcription driven by IFN was studied. The potentially functional BST2 variants were selected through a strategy of gene-wide screening. The associations of BST2 variants and polygenic score (PGS) model, which was used to quantify the combined influence of several genetic variants, with treatment response were examined in 2 separate PegIFN alpha-treated cohorts of 238 and 707 patients with CHB, respectively. We found that overexpression of BST2 improved the anti-HBV activity triggered by IFN-alpha. Among PegIFN alpha-treated patients with CHB, BST2_rs9576 was screened out to be significantly correlated with combined response (CR; i.e., HBeAg seroconversion along with HBV DNA level <3.3log(10)IU/mL, P = 7.12 x 10(-5)). Additionally, there was a strong correlation between the PGS incorporating BST2_rs9576 and other 5 genetic variations (previously described predictors of therapy response to PegIFN alpha) and CR (P = 1.81 x 10(-13)), hepatitis B surface antigen (HBsAg) level (P = 0.004), as well as HBsAg decline (P = 0.017). In conclusion, higher BST2 expression responded better to IFN-alpha treatment. BST2_rs9576 is an effective indicator to forecast therapy response of PegIFN alpha-treated patients with CHB. The PGS possesses the potential to boost the ability of PegIFN alpha therapy response.

学科与关键词

关键词
C VIRUSINFLUENZA-VIRUSTETHERINRELEASEPROTEIN
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Clinical Pharmacology and Therapeutics
发表日期
2024-02
卷期
第 115 卷, 第 2 期
页码
361-370
DOI
10.1002/cpt.3120
语言
ENGLISH
成果收录
SCIE
资助标注
National Key Research and Development Program of China [2022YFC2303600]; General Programs from the National Natural Science Foundation of China [82272765, 81472618, 81670535, 82203253]; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01S131]; GuangDong Basic and Applied Basic Research Foundation [2022A1515220090]; General Program from the Natural Science Foundation of Guangdong Province [2019A1515011423]; Innovative Research Team Project of Guangxi Province [2017GXNSFGA198002]; Dean Fund of Nanfang Hospital, Southern Medical University [2018Z005]; Grant for Recruited Talents to Start Scientific Research from Nanfang Hospital; Outstanding Youth Development Scheme of Nanfang Hospital, Southern Medical University [2017J001]; Postdoctoral Science Foundation of China [2022M711508]

作者

  • C

    Chen, Jiaxuan (第一作者)

    southern med univ · youjiang med univ nationalities

  • H

    Hou, Jia

    southern med univ

查看全部 6 位作者收起作者
  • N

    Na, Rong

    univ hong kong

  • Z

    Zhou, Bin

    southern med univ

  • H

    Hou, Jinlin (通讯)

    southern med univ

  • J

    Jiang, De-Ke (通讯)

    southern med univ · youjiang med univ nationalities

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417